Replies to post #234632 on Biotech Values

[DewDiligence]

ABUS’s AB-729 data on the 90mg cohort are generally consistent with the previously reported data from higher-dose and lower-dose cohorts of this trial—see #msg-155712858.

[DewDiligence]

ABUS_reports_additional_phase-1_data_for_AB-729_in_HBV:

https://www.globenewswire.com/news-release/2020/11/15/2126904/0/en/Arbutus-Announces-Presentation-of-Phase-1a-1b-Clinical-Trial-Results-for-AB-729-in-Chronic-Hepatitis-B-Subjects-at-The-Liver-Meeting-Digital-Experience-The-American-Association-for.html

The new data are HBsAg measurements at 12w (n=7), 16w (n=7), and 20w (n=3) for the 60mg/q4w cohort.

AB-729 is an injected RNAi agent that targets multiple HBV antigens.

ABUS and ASMB are jointly running a phase-2 trial of ABUS’ AB-729 and ASMB’s ABI-H0731 (#msg-157913492), despite the fact that ABI-H0731 is effectively obsolete (#msg-159327881).

Please see #msg-155730326, #msg-155712858, #msg-154597458, and #msg-152274693 for related info.